Zhejiang East Asia Pharmaceutical Co., Ltd. (SHA:605177)
China · Delayed Price · Currency is CNY 20.85
-0.42 (-1.97%)
Nov 6, 2026, 10:25 AM CST
SHA:605177 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,347 | 2,003 | 2,218 | 3,008 | 2,274 | 3,140 | |
Market Cap Growth | 0.24% | -9.67% | -26.27% | 32.27% | -27.57% | -22.14% |
Enterprise Value | 2,952 | 2,617 | 2,681 | 2,732 | 1,902 | 2,504 |
Last Close Price | 21.27 | 17.80 | 19.70 | 26.08 | 19.48 | 26.64 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 24.81 | 21.78 | 45.84 |
Forward PE | - | 8.48 | 10.15 | 18.20 | - | - |
PS Ratio | 2.51 | 2.13 | 1.85 | 2.22 | 1.93 | 4.41 |
PB Ratio | 1.47 | 1.11 | 1.18 | 1.49 | 1.24 | 1.79 |
P/TBV Ratio | 1.54 | 1.15 | 1.22 | 1.54 | 1.28 | 1.83 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.15 | 2.78 | 2.24 | 2.01 | 1.61 | 3.52 |
EV/EBITDA Ratio | 136.95 | 40.67 | 120.07 | 12.41 | 10.53 | 24.56 |
EV/EBIT Ratio | - | - | - | 24.43 | 21.49 | 76.37 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.55 | 0.55 | 0.42 | 0.35 | 0.07 | 0.00 |
Debt / EBITDA Ratio | 40.62 | 14.60 | 29.73 | 3.15 | 0.67 | 0.02 |
Debt / FCF Ratio | 52.62 | - | - | - | - | - |
Net Debt / Equity Ratio | 0.37 | 0.30 | 0.11 | -0.09 | -0.22 | -0.34 |
Net Debt / EBITDA Ratio | 37.22 | 8.47 | 9.50 | -0.83 | -2.26 | -5.92 |
Net Debt / FCF Ratio | 35.80 | -1.59 | -0.58 | 0.59 | 2.59 | 4.15 |
Asset Turnover | 0.30 | 0.27 | 0.35 | 0.47 | 0.50 | 0.33 |
Inventory Turnover | 1.52 | 1.22 | 1.50 | 1.83 | 2.03 | 1.52 |
Quick Ratio | 0.95 | 0.93 | 0.84 | 1.58 | 1.22 | 1.64 |
Current Ratio | 2.04 | 1.73 | 1.67 | 2.50 | 2.09 | 2.61 |
Return on Equity (ROE) | -12.07% | -4.48% | -5.18% | 6.29% | 5.80% | 3.93% |
Return on Assets (ROA) | -2.96% | -1.58% | -1.99% | 2.40% | 2.34% | 0.95% |
Return on Invested Capital (ROIC) | -6.73% | -3.93% | -5.61% | 6.17% | 6.21% | 3.06% |
Return on Capital Employed (ROCE) | -6.00% | -3.30% | -4.20% | 4.20% | 4.70% | 1.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -8.70% | -4.11% | -4.54% | 4.03% | 4.59% | 2.18% |
FCF Yield | 0.71% | -17.13% | -16.60% | -10.36% | -6.96% | -4.64% |
Dividend Yield | - | - | - | 1.22% | 1.45% | 0.72% |
Payout Ratio | - | - | - | 29.90% | 22.37% | 57.00% |
Buyback Yield / Dilution | -0.85% | -2.31% | 10.52% | -10.13% | 0.57% | -30.62% |
Total Shareholder Return | -0.85% | -2.31% | 10.52% | -8.90% | 2.02% | -29.90% |